Skip to content

Study · Non-randomized trial · n = 14 · 2018

5 results

A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.

Deeb LC, Dulude H, Guzman CB, Zhang S, Reiner BJ, Piché CA, Pradhan S, Zhang XM

Pediatric diabetes22 Mar 2018Cited by 42 (Europe PMC)

PMID29512902 (opens in a new tab)DOI10.1111/pedi.12668 (opens in a new tab)PepBankPUB-29512902
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children and adolescents with type 1 diabetes, all 33 moderate hypoglycemic events resolved within 30 minutes after nasal glucagon.

    In plain wordsIn children and adolescents with type 1 diabetes, all 33 moderate hypoglycemic events resolved within 30 minutes after nasal glucagon.

    Peptide
    Glucagon
    Outcome
    Not applicableReturn to normal status
    Study

    n = 14

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 mg · nasalAs given in this study (human).

    Measurements

    Events with recovery
    33 events
    within 30 minutes

    Source sentences

    Summary
    Patients returned to normal status within 30 minutes of NG administration in all 33 events.
    3 context sentences
    Summary · context
    The analysis population included 14 patients who experienced 33 moderate hypoglycemic events with neuroglycopenic symptoms and BG level ≤70 mg/dL.
    Summary · context
    This multicenter, open-label study was designed to evaluate real-world effectiveness and ease of use of nasal glucagon (NG) in treating moderate or severe hypoglycemic events in children and adolescents with type 1 diabetes (T1D).
    Summary · context
    Caregivers were trained to administer NG (3 mg) to the child/adolescent with T1D during spontaneous, symptomatic moderate or severe hypoglycemic events, observe treatment response (defined as awakening or returning to normal status within 30 minutes)
  2. 02HumanNon-randomized trialEfficacy outcome

    In children and adolescents with type 1 diabetes, mean glucose rose from 55.5 to 113.7 mg/dL within 15 minutes after nasal glucagon.

    In plain wordsIn children and adolescents with type 1 diabetes, nasal glucagon raised mean blood glucose from 55.5 to 113.7 mg/dL.

    Peptide
    Glucagon
    Outcome
    IncreaseBlood glucose
    Study

    n = 14

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 mg · nasalAs given in this study (human).

    Measurements

    Mean blood glucose
    55.5 mg/dL
    baseline
    Blood glucose range
    42 to 70 mg/dL
    baseline
    Mean blood glucose
    113.7 mg/dL
    within 15 minutes
    Blood glucose range
    79 to 173 mg/dL
    within 15 minutes

    Source sentences

    Summary
    Mean BG levels increased from 55.5 mg/dL (range 42-70 mg/dL) at baseline to 113.7 mg/dL (range 79-173 mg/dL) within 15 minutes of NG administration.
    2 context sentences
    Summary · context
    This multicenter, open-label study was designed to evaluate real-world effectiveness and ease of use of nasal glucagon (NG) in treating moderate or severe hypoglycemic events in children and adolescents with type 1 diabetes (T1D).
    Summary · context
    Caregivers were trained to administer NG (3 mg) to the child/adolescent with T1D during spontaneous, symptomatic moderate or severe hypoglycemic events, observe treatment response (defined as awakening or returning to normal status within 30 minutes)
  3. 03HumanNon-randomized trialOther

    For children and adolescents with type 1 diabetes, caregivers rated nasal glucagon easy or very easy in 93.9% of hypoglycemic events.

    In plain wordsFor children and adolescents with type 1 diabetes, caregivers rated nasal glucagon easy or very easy in 93.9% of events.

    Peptide
    Glucagon
    Outcome
    Not applicableEase of administration
    Study

    n = 14

    Outcome group
    Treatment Administration · Whole body
    Studied dose
    3 mg · nasalAs given in this study (human).

    Measurements

    Easy or very easy administration
    93.9%
    hypoglycemic events

    Source sentences

    Summary
    In most hypoglycemic events (93.9%), caregivers reported that NG administration was easy or very easy; they could administer NG within 30 seconds in 60.6% of events.
    2 context sentences
    Summary · context
    This multicenter, open-label study was designed to evaluate real-world effectiveness and ease of use of nasal glucagon (NG) in treating moderate or severe hypoglycemic events in children and adolescents with type 1 diabetes (T1D).
    Summary · context
    Caregivers were trained to administer NG (3 mg) to the child/adolescent with T1D during spontaneous, symptomatic moderate or severe hypoglycemic events, observe treatment response (defined as awakening or returning to normal status within 30 minutes)
  4. 04HumanNon-randomized trialOther

    For children and adolescents with type 1 diabetes, caregivers administered nasal glucagon within 30 seconds in 60.6% of events.

    In plain wordsFor children and adolescents with type 1 diabetes, caregivers gave nasal glucagon within 30 seconds in 60.6% of events.

    Peptide
    Glucagon
    Outcome
    Not applicableAdministration within 30 seconds
    Study

    n = 14

    Outcome group
    Treatment Administration · Whole body
    Studied dose
    3 mg · nasalAs given in this study (human).

    Measurements

    Administration within 30 seconds
    60.6%
    events

    Source sentences

    Summary
    In most hypoglycemic events (93.9%), caregivers reported that NG administration was easy or very easy; they could administer NG within 30 seconds in 60.6% of events.
    2 context sentences
    Summary · context
    This multicenter, open-label study was designed to evaluate real-world effectiveness and ease of use of nasal glucagon (NG) in treating moderate or severe hypoglycemic events in children and adolescents with type 1 diabetes (T1D).
    Summary · context
    Caregivers were trained to administer NG (3 mg) to the child/adolescent with T1D during spontaneous, symptomatic moderate or severe hypoglycemic events, observe treatment response (defined as awakening or returning to normal status within 30 minutes)
  5. 05HumanNon-randomized trialSafety outcome

    In children and adolescents with type 1 diabetes treated with nasal glucagon, no serious adverse events occurred.

    In plain wordsIn children and adolescents with type 1 diabetes, no serious adverse events occurred after nasal glucagon.

    Peptide
    Glucagon
    Outcome
    Not applicableSerious adverse events
    Study

    n = 14

    Outcome group
    Adverse events · Whole body
    Studied dose
    3 mg · nasalAs given in this study (human).

    Source sentences

    Summary
    There were no serious adverse events.
    2 context sentences
    Summary · context
    This multicenter, open-label study was designed to evaluate real-world effectiveness and ease of use of nasal glucagon (NG) in treating moderate or severe hypoglycemic events in children and adolescents with type 1 diabetes (T1D).
    Summary · context
    Caregivers were trained to administer NG (3 mg) to the child/adolescent with T1D during spontaneous, symptomatic moderate or severe hypoglycemic events, observe treatment response (defined as awakening or returning to normal status within 30 minutes)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.